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A B S T R A C T
This is a protocol for a Cochrane Review (Prognosis). The objectives are as follows:
Endocrine therapy for breast cancer prevention has been shown to reduce risk, and for treatment of early stage oestrogen receptor-
positive (ER-positive) breast cancer to reduce breast cancer mortality. The objective of the review is to synthesise available evidence on
whether mammographic density reduction in these settings is (i) a prognostic biomarker and (ii) a predictive biomarker, as defined in the
Introduction. We will explore sources of heterogeneity to identify the impact of differences in participants, measures of mammographic
density, follow-up length and study design. Within the prognostic and predictive biomarker reviews, our analysis will consider prevention
and treatment populations separately, and within these, selective oestrogen receptor modulators (SERMs) and aromatase inhibitors
(AIs) separately.
B A C K G R O U N D
Description of the condition and intervention
Breast cancer is the most common cancer in women worldwide,
the second most frequent cause of cancer death in women from
high-income regions and the most common cause of death in low-
income regions (Ferlay 2013). Two types of drugs have shown ef-
ficacy for both prevention and treatment of certain subtypes of the
disease. The first are called selective oestrogen receptor modula-
tors (SERMS). They prevent breast cancer (Cuzick 2013; Cuzick
2015), and are also used in adjuvant settings to reduce the chance
that breast cancer will reoccur when it has been diagnosed at an
early stage (Davies 2011; EBCTCG 1998). The second are called
aromatase inhibitors (AIs). AIs are suitable for postmenopausal
women only, and they confer greater average reductions in the risk
of breast cancer (Cuzick 2014; Visvanathan 2013), and recurrence
than SERMs (EBCTCG 2015).
Description of the biomarker
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The breast is made up of glandular and supportive tissue. Glan-
dular tissue is the network that produces and transports milk to
the nipple; the supportive tissue is largely fat but also contains
fibrocollagenous tissue called glandular stroma. Glandular tissue
and glandular stroma appear as a white area on a mammogram
(breast x-ray), which is called mammographic density (Assi 2011).
Breast density is a strong risk factor for breast cancer, and women
with mostly dense breasts have approximately four times the risk
of breast cancer than women of the same age and weight with
mostly fatty breasts (Huo 2014; McCormack 2006). Mammo-
graphic density is also associated with classical reproductive risk
factors, and it is lower in women who have had children and breast
fed (Boyd 1998).
How the biomarker might be related to
treatment response
Hormonal treatment can change a woman’s mammographic den-
sity. Density increases during use of hormone replacement therapy
(HRT) and HRT is also a risk factor for breast cancer (McTiernan
2005; Rutter 2001). After cessation of HRT, mammographic den-
sity may decrease in as little as four weeks (Harvey 1997), and it is
likely that within a couple of years the woman will have the same
level of risk as a woman who has never used HRT (Beral 2011).
Breast density may also decrease during SERM therapy above that
expected due to age (Cuzick 2004), but the evidence for AIs is less
clear (Engmann 2017; Vachon 2013).
The association between hormonal treatment and density change
is well documented, and there is also direct evidence that the
increased risk from combination HRT is mediated by mammo-
graphic density (Boyd 2006; Byrne 2017; Martin 2009). Find-
ings for prevention (Cuzick 2011a), and treatment (including Kim
2012; Ko 2013; Li 2013; Nyante 2015; Vachon 2013), also sug-
gest that change in breast density is an appropriate biomarker for
response to SERMs. A working hypothesis is therefore that mam-
mographic density reductions in women receiving endocrine ther-
apy for treatment or prevention might indicate who is responding
to therapy, making it a reliable surrogate outcome. The precise
mechanism is still unclear and is an area of active research, but one
theory is that decreases in density arise when a woman is able to
metabolise the drug effectively (Jordan 2007).
Why it is important to do this review
The first aim of this review is to assess the evidence that change in
mammographic density is a prognostic biomarker (Altman 2001).
We define the term prognostic biomarker to be a measure that is
associated with a clinical outcome of interest in a defined group of
patients. This terminology is standard when the group of patients
has a health condition such as breast cancer, but it perhaps is less
frequently used for risk factors in healthy patients when the clinical
outcome is breast cancer.
Several prognostic factors for women diagnosed with breast can-
cer have been identified. These include classical factors such as
tumour size, grade and lymph node involvement, and biomarkers
including Ki67 and commercial genetic signatures such as On-
cotypeDX (Cuzick 2011b; Harris 2007). Prognostic factors for
healthy women without breast cancer (or risk factors) include age,
a family history of the disease, and hormonal and reproductive
factors including weight and age at first child (Tyrer 2004). Quan-
tifying the effect of potential prognostic factors on outcomes is
important for many reasons. It may be used to help guide clinical
decision making, improve understanding of disease, improve the
design and analysis of trials, and improve risk assessment (Riley
2013).
The second aim of this review is to assess the evidence that change
in mammographic density is a predictive biomarker, which is
taken to be a measure that is differentially associated with response
to treatment (Hingorani 2013). Some, but not all, prognostic
biomarkers are predictive biomarkers. Two examples for women
with breast cancer are human epidermal growth factor receptor
(HER-2) and oestrogen receptor (ER) status. HER-2 was identi-
fied as a prognostic factor for breast cancer and provided a target
for a treatment (trastuzumab), which was subsequently shown to
be effective for women with HER-2 breast cancer. ER status is a
prognostic biomarker and a predictive biomarker for SERM and
AI treatments: they have been shown to improve clinical outcomes
only in ER-positive patients.
There is currently no systematic review that focuses on the evi-
dence that mammographic density reductions in women receiv-
ing endocrine therapy are prognostic or predictive biomarkers.
However, some other reviews on the topic have been published,
most recently the Shawky 2017 study. This reported seven studies
of density change as a prognostic factor for women receiving a
SERM or AI, but no data from a randomised trial or otherwise
to evaluate change in mammographic density after initiation of
adjuvant tamoxifen treatment as a predictive biomarker. For pre-
vention there has been one study to evaluate density change as a
prognostic and predictive biomarker for prevention, which was a
case-control study from within a randomised trial.
It is important to undertake this review because findings are likely
to be important to: clinicians and their patients undergoing or
considering endocrine therapy, such as by helping to define risk
groups and to better predict outcomes; regulators and ethics boards
considering trials of products that use mammographic density re-
ductions as an endpoint; those with an interest in mechanisms
by which endocrine therapy improves clinical outcomes. Addi-
tionally, as discussed in the Mullooly 2016 study, had the ran-
domised trials of SERMS and AIs included density change as a
potential prognostic or predictive biomarker, then different con-
clusions might have been reached regarding their effectiveness: it is
possible that women with density reductions from a SERM might
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have greater benefits from this treatment than from an AI. Another
possibility is that women who see density increases following a
short-term decrease might show resistance to the treatment.
O B J E C T I V E S
Endocrine therapy for breast cancer prevention has been shown
to reduce risk, and for treatment of early stage oestrogen receptor-
positive (ER-positive) breast cancer to reduce breast cancer mor-
tality. The objective of the review is to synthesise available evi-
dence on whether mammographic density reduction in these set-
tings is (i) a prognostic biomarker and (ii) a predictive biomarker,
as defined in the Introduction. We will explore sources of het-
erogeneity to identify the impact of differences in participants,
measures of mammographic density, follow-up length and study
design. Within the prognostic and predictive biomarker reviews,
our analysis will consider prevention and treatment populations
separately, and within these, selective oestrogen receptor modula-
tors (SERMs) and aromatase inhibitors (AIs) separately.
M E T H O D S
We will write this review according to PRISMA guidelines
(Liberati 2009), while supplemented as necessary for a predictive
and prognostic biomarker review, and will follow the REMARK
guidelines (Altman 2012; McShane 2005). We plan to conduct a
literature-based analysis to identify relevant studies and then meta-
analytic methods. Subsequently, we will seek individual-level data
from those studies included in order to conduct further analysis
that may better account for heterogeneity between the studies in
aspects such as definition of the biomarker and cutpoints used. We
will develop a separate protocol for data extraction and statistical
analysis of this subsequent study.
Criteria for considering studies for this review
Our review question will include studies with the following de-
signs, participants, interventions, biomarkers and outcomes.
Types of study designs
We will include the same study designs for both the prognostic
and predictive review. We will include randomised and non-ran-
domised observational studies (prospective and retrospective co-
hort and case-control studies). We will separately treat exploratory
biomarker studies in the analysis, where density is one of several
biomarkers considered simultaneously (this is unlikely).
Types of participants
We will include the same type of participant for the prognostic
and predictive biomarker reviews. We will include all adult women
aged 18 years or more, with or without breast cancer (denoted
respectively as treatment, prevention), based on the following cri-
teria.
Treatment: women with early stage hormone receptor- (oestrogen
(ER) or progesterone (PgR)) positive breast cancer. This is defined
to be women who have had histologically-proven operable invasive
hormone receptor-positive breast cancer or ductal carcinoma in
situ (DCIS), and were candidates to receive endocrine adjuvant
therapy; there was no clinical evidence of metastatic disease. In
addition, women are ineligible if breast density measurements were
not possible on a contralateral breast or if they had bilateral breast
cancer.
Prevention: women who have not previously been diagnosed with
invasive breast cancer or DCIS. There are no exclusions for level
of increased risk due to genetic factors (including BRCA1/2 gene
mutations or a family history of the disease, or both) or otherwise
assessed by an absolute or relative risk prediction model. We will
exclude women with breast implants or those who have under-
gone risk-reducing mastectomies because accurate breast density
estimation is not possible.
Women must be at risk for at least the length of time between
baseline and follow-up mammogram. We will include women who
might have changed treatment or discontinued treatment through-
out follow-up, but will exclude women who changed treatment
between the mammograms for density change (we will not exclude
those who discontinued). We will exclude women who received
another selective oestrogen receptor modulator (SERM) or aro-
matase inhibitor (AI) before treatment.
For AI comparisons women must be postmenopausal at the start
of treatment; for SERM comparisons they may be pre or post-
menopausal. Postmenopausal women will include women having
had a bilateral oophorectomy; or aged more than 60 years; or aged
40 to 59 years with an intact uterus and amenorrhoeic for at least
12 months. We will exclude women rendered temporarily post-
menopausal through medical interventions (e.g. gonadotropin-re-
leasing hormone (GnRH) analogues).
We will include studies that include subsets of relevant participants




We will define the same types of intervention for the prognostic
and predictive biomarker reviews.
We will include women receiving SERMs at the following mini-
mum doses (Komm 2014): Tamoxifen, 20 mg daily; Raloxifene,
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60 mg daily; Lasofoxifene, 0.25 mg daily; Arzoxifene, 20 mg daily;
Droloxifene, 40 mg daily; Bazedoxifene, 20 mg daily; and Fulves-
trant, 250 mg monthly.
We will include women receiving AIs at the following minimum
doses: Anastrozole, 1 mg daily; Letrozole, 2.5 mg daily; and Ex-
emestane, 25 mg daily. All treatments are oral, except Fulvestrant
(intramuscular). Women must receive treatment for at least the
length of time between baseline and follow-up mammogram (i.e.
at least 1 year). We will include studies of women receiving doses
lower than these doses for a secondary dose-response analysis, but
will exclude them from the main analysis. We will include studies
that are a mix of women including SERMs and AIs in the primary
analysis if we can separate results; otherwise we will include them
only in secondary analyses.
Cointerventions
We will allow the same types of cointervention for the prognostic
and predictive biomarker reviews.
For treatment, women are ineligible if they had not completed
primary locoregional (surgery or radiotherapy, or both) treatment
and systemic (chemotherapy or targeted therapy) treatment (where
indicated) with curative intent (either in neoadjuvant or in ad-
juvant setting). Women are ineligible if there was a gap of more
than eight weeks between different treatment interventions, for
example, between surgery and start of radiotherapy. Women are
also ineligible if they had received endocrine therapy for breast
cancer prevention before diagnosis of breast cancer or if endocrine
treatment was started before surgery and received for more than
28 days.
We will include studies if some women use or used (up to 2 years
before baseline) hormone replacement therapy (HRT) (prevention
and treatment), but we will note this, including in the ’Risk of
bias’ assessment. We will permit other cointerventions, including
exercise and diet advice, but we will identify them where possible,
including in the ’Risk of bias’ assessment.
Comparators
The main difference between the prognostic and predictive
biomarker review is the comparator.
Prognostic biomarker review
The comparison is within each intervention group (SERM or AI),
where the outcome is related to the change in density over the
period. This will help assess whether the biomarker is associated
with the outcome in those receiving SERM or AI interventions,
i.e. a prognostic biomarker.
Predictive biomarker review
The predictive biomarker review will make a comparison between
the intervention group and a control group from the same study.
The within-study comparator group will be a corresponding ran-
domised placebo group, or a non-randomised control group of
women not receiving endocrine therapy.
Biomarker
We will use the same definition of biomarker for the prognostic
and predictive reviews.
A measure of mammographic density is required at baseline (start
of endocrine therapy or study entry in those from the control
group) and follow-up. We will include studies with baseline mam-
mograms obtained before or after diagnosis and before the start of
therapy (treatment) and up to two years before the diagnosis, and
a follow-up mammogram performed 90 days to three years after
therapy start (or study entry), with the density closest to one year
from the start of endocrine therapy, if there is a choice. We will
record the range and average time between baseline mammogram
and diagnosis, between diagnosis and start of endocrine therapy
(or study entry), and between start of endocrine therapy (or study
entry) and the follow-up mammogram.
We will include any density method that has been shown in more
than one study, outside of the review studies, to have a relation-
ship with breast cancer risk. This will include, but not be limited
to, the following percentage methods: (i) visual assessment by ex-
pert in 5% bands; (ii) visual assessment by expert in 20% bands
(Boyd categories); (iii) visual assessment by expert as continuous
percentage (%); (iv) semi-automated thresholding such as using
CUMULUS software (Byng 1994) by expert (or trained) reader;
(v) fully-automated (based on area of density); and (vi) fully-auto-
mated volumetric percentage (e.g. Volpara, Highnam 2010). We
will also consider the following categorical measures: (i) BI-RADS
density (D’Orsi 2013); (ii) Wolfe grade (Wolfe 1976); and (iii)
Tabar grade (Gram 1997). We will also consider absolute dense
area or volume from: (i) semi-automated methods (including CU-
MULUS); (ii) automated area-based methods; and (iii) fully-au-
tomated volumetric methods.
We will also consider information on reliability of density mea-
sures, including correlation between repeated measures from re-
peat mammograms, intraclass correlation coefficients and Bland-
Altman limits of agreement (Bland 1999), whether different in-
terpreters of density were used, whether the same reader assessed
change in density, whether the reader was blinded to case status,
whether the reader was blinded to treatment allocation, whether
randomisation was per mammogram (mammograms read inde-
pendently) or per woman (mammograms for each woman read
with the knowledge of her other mammograms), and whether the
order of per woman mammograms was sequential or random and
assessed one at a time or simultaneously. We will use these for a
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qualitative assessment of potential bias due to measurement of the
biomarker.
We will not include women or studies that have different defi-
nitions or measures of mammographic density between the time
points used to assess change.
Types of outcome measures
We will use the same outcome measures for the prognostic and
predictive reviews.
Primary outcomes
Potential benefits from treatment
• Treatment: breast cancer mortality (time to death caused by
breast cancer)
• Prevention: incidence of invasive breast cancer and DCIS
Potential harms from treatment
• Treatment and prevention: rate of all serious adverse events.
These include serious side effects noted for Tamoxifen (cataracts,
pulmonary embolism or deep vein thrombosis and endometrial
cancer) and Anastrozole (osteoporosis and bone fractures).
Secondary outcomes
Potential benefits from treatment
• Treatment: recurrence
• Treatment: incidence of a secondary primary breast cancer
(e.g. in the contralateral breast)
• Treatment: any recurrence or any death (disease-free
survival)
• Treatment: distant metastases
• Treatment: death from all causes (all-cause mortality)
• Treatment: recurrence of invasive cancer only
• Treatment: recurrence of DCIS cancer only
• Prevention: incidence of invasive cancer only
• Prevention: incidence of DCIS cancer only
Potential harms from treatment
• Treatment and prevention: troublesome but not serious side
effects observed for SERMs and AIs, including vasomotor
symptoms and joint or muscle pain.
’Summary of findings’ table for assessing the quality of the
evidence
We will produce different ’Summary of findings’ tables for the
prognostic and predictive biomarker reviews, but based on the
same outcomes. We will apply methods following the approach
outlined by GRADE (Schunemann 2011), using GRADEpro
GDT software (GRADEpro GDT). The seven main outcomes to
be reported are as follows.
• Treatment: breast cancer mortality (time to death caused by
breast cancer).
• Prevention: incidence of invasive and DCIS.
• Treatment and prevention: the rate of all serious adverse
events. These include serious side effects noted for Tamoxifen
(cataracts, pulmonary embolism or deep vein thrombosis and
endometrial cancer) and Anastrozole (osteoporosis and bone
fractures).
• Treatment: recurrence.
• Treatment: any recurrence or any death (disease-free
survival).
• Treatment: death from all causes (all-cause mortality).
• Treatment and prevention: troublesome but not serious side
effects observed for SERMs and AIs, including vasomotor
symptoms and joint or muscle pain.
Search methods for identification of studies
Electronic searches
We will search the following databases.
• The Cochrane Breast Cancer Group’s (CBCG’s) Specialised
Register. Details of the search strategies used by the Group for
the identification of studies and the procedure used to code
references are outlined in the Group’s website (
breastcancer.cochrane.org/specialised-register). We will extract
and consider for inclusion in the review trials with the key words
“Tamoxifen, Raloxifene, Lasofoxifene, Arzoxifene, Droloxifene,
Bazedoxifene, Fulvestrant, Anastrozole, Letrozole, Exemestane,
selective estrogen receptor modulator, aromatase inhibitor”.
• CENTRAL (the Cochrane Library, latest issue). See
Appendix 1.
• MEDLINE (via OvidSP) from 1996 to present. See
Appendix 2.
• Embase (via OvidSP) from 1996 to present. See Appendix
3.
• The World Health Organization ( WHO) International
Clinical Trials Registry Platform ( ICTRP) search portal (
apps.who.int/trialsearch) for all prospectively registered and
ongoing trials. See Appendix 4.
• ClinicalTrials.gov ( ClinicalTrials.gov). See Appendix 5.
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Searching other resources
• Bibliographic searching
We will try to identify further studies from reference lists of iden-
tified relevant trials or reviews. We will obtain a copy of the full ar-
ticle for each reference reporting a potentially eligible trial. Where
this is not possible, we will make attempts to contact study authors
to provide additional information.
Data collection and analysis
Selection of studies
Two review authors (AB and EA) will independently review all
titles and abstracts retrieved to assess eligibility against inclusion
criteria. If a review author has published a potentially eligible study,
two other authors (EA and MT) will review the study for eligibility.
One author (AB or EA) will obtain full-text copies of all papers
and two review authors (AB and EA) will review the full texts. Any
disagreement at this stage will be resolved by one review author
(MT) and the included and excluded studies will be recorded.
We will contact authors of primary studies for clarification, if
necessary. We will record duplicate studies as one reference (e.g.
the same study but multiple papers with slightly different aims
or follow-up). We will only include studies published in English.
We will record the selection process in a PRISMA flow diagram
(Liberati 2009) in Review Manager 5 software (Review Manager
2014). We will record the process using the Covidence system
(Covidence 2018).
Data extraction and management
Two review authors (AB and EA) will independently complete
data extraction using custom forms. One review author (MT) will
resolve disagreement. We will automatically extract the forms into
a custom database. We will collect the following information.
• Study design: type of study. For example, a nested case-
control study from a randomised trial, or a non-randomised
cohort study, or a case-control study. If there is matching, then
what was matching by and to what level (e.g. age to plus/minus 2
years). Control group: yes/no (women without treatment).
Whether prognostic or predictive study, or both. For prognostic
factor study, what phase (following Altman 1998; Riley 2009).
• Participants: demographic information, including number
of participants, age, body mass index (BMI), ethnicity,
education. Summary statistics such as mean, interquartile range
(or standard deviation) and range for age, BMI and absolute or
relative baseline risk, or both, from a risk model (e.g. Gail model
(Gail 1989), Tyrer-Cuzick (Tyrer 2004), BCSC (Tice 2008)).
Total number and total number (percentage) postmenopausal,
perimenopausal or premenopausal. For a predictive review, the
previous variables are to be split by treatment or control group.
• Biomarker: whether mammograms were from film
(digitised for density or not) or full field digital mammography.
Manufacturer of digital mammogram machine. Whether any
preprocessing was carried out for quality control of
mammographic density. Density measure(s), and the range and
average time between baseline mammogram and diagnosis,
between diagnosis and start of endocrine therapy (or study
entry), and between start of endocrine therapy (or study entry)
and the follow-up mammogram.
• Setting: country, whether in a high-risk clinic, a treatment
clinic, time period, urban/rural.
• Cointerventions: HRT use, chemotherapy use (treatment),
targeted therapy use (treatment), radiotherapy use (treatment),
neoadjuvant endocrine therapy use (treatment).
• Follow-up time period: minimum, mean, median,
interquartile range, standard deviation, maximum follow-up.
• Sources of funding and stated conflicts of interest:
descriptive text copied from sections in each paper.
When publications pertain to more than one publication, we will
extract the data from all publications and record them in the
database as such. We will consider the most recent or up-to-date
reference (largest number of participants, or longest follow-up
time, or correction to previous analysis) as the primary reference.
Assessment of risk of bias in included studies
For the prognostic review, we will use a version of the QUIPS
tool (Hayden 2013), modified for our study (Table 1), in order
to assess the risk of bias (Hayden 2006). This tool will assess six
important domains that might affect bias from included studies: (i)
study participation, (ii) attrition, (iii) measurement of density, (iv)
measurement of the outcomes, (v) confounding, and (vi) statistical
analysis.
For the predictive biomarker review, we will augment the QUIPS
tool with the ROBINS-I tool (Sterne 2016; Table 2; Table 3). This
tool will assess the risk of bias in estimation of an interaction be-
tween mammographic density change and treatment. Two review
authors (AB and EA) will independently assess the studies with
disagreements resolved by another review author (MT). If a review
author is an author of an included study, two other review authors
(EA and MT) will independently complete data extraction and
assess the study for risk of bias for that study.
For both prognostic and predictive biomarker reviews, we plan to
consider the included studies together but with a narrative identi-
fying the risk in different domains across studies. We will exclude
studies that have substantial potential for bias in a sensitivity anal-
ysis of results.
Measures of biomarker response
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Effect measure
In both reviews, the primary measure we will look for will be the
mean effect over a five-year follow-up period. We will allow other
time periods, but if split into different periods (e.g. 0 to 5 years;
5 to 10 years) then periods outside the initial five years would be
in a secondary analysis. Meta-analysis results will be subgroups
by similar cutpoints and by those using continuous trends. We
will report the ratios so that less than 1.0 favours a risk reduction
associated with a decrease in mammographic density and greater
than 1.0 indicates a risk increase.
Prognostic biomarker review
The primary measure will be a hazard ratio (cohort study with
time to event) or an odds ratio (case-control study) for the effect
of density change. We will treat an odds ratio as an equivalent
measure of the hazard ratio, unless rates are high. In this case, we
would include the odds ratio estimates in a secondary analysis.
Predictive biomarker review
The primary measure will be the interaction between treatment
and the biomarker, expressed as a relative hazard (cohort study) or
odds ratio (case-control study).
Adjustment
Prognostic biomarker review
The primary effect estimate will be adjusted. We will include un-
adjusted estimates if adjusted estimates are not available. To mea-
sure the prognostic ability of factors it is commonly accepted that
effect estimates that are adjusted for potential confounders are
more relevant than unadjusted ones (Riley 2013). However, when
adjusted estimates are not available then unadjusted estimates will
be used because we do not expect the change in density to be as-
sociated with the baseline value of most other prognostic factors,
although we acknowledge that changes in BMI may also occur,
and since BMI is negatively associated with breast density and a
prognostic factor one would ideally adjust for this in the analysis.
Predictive biomarker review
The primary effect estimate will be adjusted. There are currently
no established predictive biomarkers for either prevention or treat-
ment in the groups of women to be included that were defined
above.
Dealing with missing data
Where data are missing, we will contact study authors in an at-
tempt to obtain the data.
Assessment of heterogeneity
We will measure heterogeneity using the estimated variance in a
random-effects model (Tau2). We will assess publication bias using
a funnel plot and Egger’s test (Egger 1997).
Subgroup analysis and investigation of heterogeneity
When sufficient studies exist, we will conduct the following a priori
subgroup analysis to explore reasons for heterogeneity within the
predefined homogeneous groups above.
Between-studies
• Drug within SERM (Tamoxifen, Raloxifene, Lasofoxifene,
Arzoxifene, Droloxifene, Bazedoxifene, Fulvestrant) and AI
grouping (Anastrozole, Letrozole, Exemestane)
• Type of study: case-control, observational cohort,
randomised trial (nested case-control)
• Type of cancer at baseline (treatment): (percentage DCIS)
• Severity of cancer at baseline (treatment): stage (percentage
regional spread)
• Cointerventions (treatment): chemotherapy/targeted
therapy
• Hormone therapy use during therapy (yes/no, percentage if
available), or in previous two years (yes/no, percentage if
available)
• Time between start of therapy (or study entry) and follow-
up mammogram (mean and range)
• Menopausal status (percentage premenopausal)
• Age (mean)
• BMI (mean)
• Digital or film mammography (percentage digital)
• Distribution of density at baseline (some studies may
exclude women with low density)
Within-study estimates of effect
• Type of cancer at baseline (treatment): DCIS versus invasive
• Severity of cancer at baseline (treatment): stage (percentage
regional spread)
• Cointerventions (treatment): chemotherapy/targeted
therapy
• Hormone therapy use: no HRT prior to endocrine therapy,
some HRT two years or more than two years prior to endocrine
therapy, some HRT less than two years prior to endocrine
therapy, some HRT during endocrine therapy
• Menopausal status (pre, peri or postmenopausal)
• Age group (< 50 years or ≥ 50 years) as a proxy for
menopausal status
• BMI (both within-study (< 25, 25 to < 30, 30 to < 35, > 35
kg/m2) and between-studies (mean))
• Baseline density
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Data synthesis
Heterogeneity between studies is expected in this review because
in general it is common in reviews of prognostic biomarkers (Riley
2013). To address this we will only consider to undertake meta-
analysis for studies within predefined groups that we believe ho-
mogenous enough in advance to be meaningful for data synthesis.
Namely, those with the same class of drug, same outcome, same
density measure, same effect measure (same cutpoint or continu-
ous variable assessment). Where more than one study is available
we will combine estimates using an inverse-variance weighting
(fixed-effect estimation); if there is substantial variability then we
will present the result but state that the overall effect estimate has
very limited interpretation, while we will seek subgroups (above)
that best explain the heterogeneity.
Meta-analysis of the studies using individual data from patients
may overcome many of the expected issues arising in this review
of published data, including heterogeneity in the biomarker used
and cutpoints (Riley 2009; Riley 2013). We will use the review to
identify relevant studies, and invite the best quality studies (using
information from the ’Risk of bias’ analysis) to share data for an
individual participant-level review.
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A D D I T I O N A L T A B L E S
Table 1. Adapted QUIPS ’Risk of bias’ assessment instrument for prognostic factor studies
Biases Issues to consider for judging overall rating of risk of bias
Instructions to assess the risk of each potential bias These issues will guide your thinking and judgement about
the overall risk of bias within each of the six domains. These
issues are taken together to inform the overall judgement of
potential bias for each of the six domains
1. Study participation Goal: to judge the risk of selection bias (likelihood that relation-
ship between density reductions and outcome is different for par-
ticipants and eligible non-participants)
Source of target population The source population or population of interest is adequately de-
scribed for: a) treatment: (i) proportion with DCIS, (ii) cointer-
ventions (chemotherapy/targeted therapy), (iii) severity of cancer
at baseline (stage, % regional spread); b) prevention: level of risk
in population, including whether some or all are BRCA1/2 mu-
tation carriers, (ii) prior hormone replacement therapy use, (iii)
cointerventions such as diet or exercise regimens, or both
Method used to identify population The sampling frame and recruitment are adequately described,
including methods to identify the sample sufficient to limit po-
tential bias
Recruitment period Period of recruitment is adequately described.
Place of recruitment Place of recruitment (setting and geographic location) are ade-
quately described
Inclusion and exclusion criteria Inclusion and exclusion criteria are adequately described.
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Table 1. Adapted QUIPS ’Risk of bias’ assessment instrument for prognostic factor studies (Continued)
Adequate study participation There is adequate participation in the study by eligible individuals
Baseline characteristics The baseline study sample (i.e. individuals entering the study)
is adequately described for (treatment and prevention) age,
menopausal status, cointerventions; (treatment) % DCIS, disease
severity; (prevention) breast cancer risk, prior hormone replace-
ment therapy use
Summary study participation The study sample represents the population of interest on key
characteristics, sufficient to limit potential bias of the observed
relationship between density change and outcome
2. Study attrition Goal: to judge the risk of attrition bias (likelihood that relation-
ship between density reductions and outcome are different for
completing and non-completing participants)
Proportion of baseline sample available for analysis Response rate (i.e. proportion of study sample allocated treatment
who received treatment) is adequate
Attempts to collect information on participants who dropped out Attempts to collect information on participants who dropped out
of the study are described
Reasons and potential impact of subjects lost to follow-up Reasons for loss to follow-up are provided.
Outcome and prognostic factor information on those lost to fol-
low-up
Participants lost to follow-up are adequately described for age
at entry and cointerventions (if any), and for a) treatment: (i)
DCIS, (ii) disease severity; b) prevention: (i) risk of breast cancer
including BRCA1/2 carriers and testing. Whether loss to follow-
up or inability to retrieve mammograms, or both, was likely related
to the study outcome
Study attrition summary There are no important differences between these characteristics
in participants who completed the study and those who did not.
Loss to follow-up (from baseline sample to study population anal-
ysed) is not associated with key characteristics (i.e. the study data
adequately represent the sample) sufficient to limit potential bias
to the observed relationship between density change and outcome
3. Prognostic factor measurement Goal: to judge the risk of measurement bias related to how mam-
mographic density was measured (differential measurement of
mammographic density related to the level of outcome)
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Table 1. Adapted QUIPS ’Risk of bias’ assessment instrument for prognostic factor studies (Continued)
Definition of the prognostic factor A clear definition or description of mammographic density is pro-
vided (e.g. including the method of measurement, if subjective
then who undertook it, if treatment then whether contralateral
breast assessed)
Valid and reliable measurement of prognostic factor Method of mammographic density change measurement is ade-
quately valid and reliable to limit misclassification bias (e.g. may
include relevant outside sources of information on measurement
properties; also characteristics, such as measurement blinded to
case status)
Continuous variables are reported or appropriate cutpoints (i.e.
not data-dependent (except for percentiles)) are used
Method and setting of prognostic factor measurement The method and setting of measurement of mammographic den-
sity is the same for all study participants. The same mammogram
type (film/digital) is used for both baseline and follow-up. The
time at which baseline and follow-up mammograms have low vari-
ability between participants
Proportion of data on prognostic factor available for analysis Adequate proportion of the study sample has complete data for
the change in mammographic density variable
Method used for missing data Appropriate methods of imputation are used for missing mam-
mographic density data
Summary Prognostic factor is adequately measured in study participants to
sufficiently limit potential bias
4. Outcome measurement Goal: to judge the risk of bias related to the measurement of out-
come (differential measurement of outcome related to the density
reductions)
Definition of the outcome A clear definition of outcome is provided, including duration of
follow-up and level and extent of the outcome construct
Valid and reliable measurement of outcome The method of outcome measurement used is adequately valid
and reliable to limit misclassification bias
Method and setting of outcome measurement The method and setting of outcome measurement is the same for
all study participants, including by age and obesity groups
Outcome measurement summary Outcome of interest is adequately measured in study participants
to sufficiently limit potential bias
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Table 1. Adapted QUIPS ’Risk of bias’ assessment instrument for prognostic factor studies (Continued)
5. Study confounding Goal: to judge the risk of bias due to confounding (i.e. the effect
of density reductions is distorted by another factor that is related
to density reductions and the outcome)
Important confounders measured Age, BMI, or another measure of adiposity are measured.
Definition of the confounding factor Clear definitions are provided.
Valid and reliable measurement of confounders Measurement of all important confounders is adequately valid and
reliable
Method and setting of confounding measurement The method and setting of confounding measurement are the
same for all study participants
Method used for missing data Appropriate methods are used if imputation is used for missing
confounder data
Appropriate accounting for confounding The primary analysis will be adjusted for at least age, either
through the study design and analysis, or through adjustment in
the analysis only; and other prognostic factors
Study confounding summary Important potential confounders are appropriately accounted for,
limiting potential bias with respect to the relationship between
prognostic factor and outcome
6. Statistical analysis and reporting Goal: to judge the risk of bias related to the statistical analysis and
presentation of results
Presentation of analytical strategy,
model development strategy
There is sufficient presentation of data to assess the adequacy of
the analysis
Model development strategy The strategy for model building (i.e. inclusion of variables in
the statistical model) is appropriate and is based on a conceptual
framework or model
Reporting of results The selected statistical model is adequate for the design of the
study. There is no selective reporting of results
Statistical analysis and presentation summary The statistical analysis is appropriate for the design of the study,
limiting potential for presentation of invalid or spurious results
BMI: body mass index
DCIS: ductal carcinoma in situ
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Table 2. ROBINS-I tool (stage 1): treatment
List of confounding domains relevant to all or most studies (prognostic factors that predict whether an individual receives a SERM/
















HER: human epidermal growth factor receptor
SERM/AI: selective oestrogen receptor modulator/aromatase inhibitor
Table 3. ROBINS-I tool (stage 1): prevention
List of confounding domains relevant to all or most studies (prognostic factors that predict whether an individual receives a SERM/




Family history of disease
Hormone replacement therapy use
Benign breast disease
Previous cancer other than breast cancer
Ethnicity
List of cointerventions that could be different between intervention groups and that could impact on outcome
Hormone replacement therapy
Risk-reducing surgery
SERM/AI: selective oestrogen receptor modulator/aromatase inhibitor
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A P P E N D I C E S
Appendix 1. CENTRAL
#1 MeSH descriptor: [Selective Estrogen Receptor Modulators] explode all trees
#2 MeSH descriptor: [Aromatase Inhibitors] explode all trees
#3 MeSH descriptor: [Tamoxifen] explode all trees
#4 tamoxifen
#5 MeSH descriptor: [Raloxifene Hydrochloride] explode all trees
#6 raloxifene or lasofoxifene or arzoxifene or droloxifene or bazedoxifene or fulvestrant or anastrozole or letrozole or exemestane
#7 #1 or #2 or #3 or #4 or #5 or #6
#8 MeSH descriptor: [Breast Density] explode all trees
#9 (mammogr* or breast or mammary) near dens*
#10 MeSH descriptor: [Mammography] explode all trees
#11 MeSH descriptor: [Mammary Glands, Human] explode all trees
#12 dens*
#13 (#10 or #11) and #12
#14 #8 or #9 or #13
#15 #7 and #14
Appendix 2. MEDLINE via OvidSP
1 exp Selective Estrogen Receptor Modulators/
2 exp Aromatase Inhibitors/
3 exp TAMOXIFEN/
4 tamoxifen.mp.
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16 exp Breast Density/
17 exp MAMMOGRAPHY/
18 exp Mammary Glands, Human/
19 ((mammogr* or breast or mammary) adj6 dens*).tw.
20 dens*.tw.
21 (17 or 18) and 20
22 16 or 19 or 21
23 15 and 22
24 Animals/ not Humans/
25 23 not 24
26 limit 25 to yr=“1996 -Current”
Appendix 3. Embase via OvidSP
# Searches
1 exp selective estrogen receptor modulator/
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24 exp breast density/
25 ((mammogr$ or breast or mammary) adj6 dens$).ti,ab.
26 dens$.ti,ab.
27 exp mammography/
28 exp mammary gland/
29 26 and (27 or 28)
30 24 or 25 or 29
31 23 and 30
32 limit 31 to (human and (conference abstracts or embase) and yr=“1996 -Current”)
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Appendix 4. WHO ICTRP
Basic search:




Intervention: selective oestrogen receptor modulator OR serm OR aromatase inhibitor OR tamoxifen OR raloxifene OR lasofoxifene




Condition or disease: breast cancer
Other terms: breast density OR mammographic density
Study type: All studies
Study results: All studies
Sex: All
Intervention/treatment: selective oestrogen receptor modulator OR serm OR aromatase inhibitor OR tamoxifen OR raloxifene OR
lasofoxifene OR arzoxifene OR droloxifene OR bazedoxifene OR fulvestrant OR anastrozole OR letrozole OR exemestane
C O N T R I B U T I O N S O F A U T H O R S
The objectives and aims of the review were discussed and agreed by all authors. ARB drafted the protocol. It was updated to address
critiques from EA, MT, JC and peer-reviewers. All authors agreed the final version.
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